Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Conagra Brands Inc (CAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Conagra Brands Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.74 (market cap $29.60B), while Conagra Brands Inc trades at $15.01 (market cap $7.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.1× Conagra Brands Inc's market cap, and Conagra Brands Inc pays a 8.2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CAG | |
|---|---|---|
Market Cap | $29.60B | $7.14B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $20.02 |
52-Week Low | $205.48 | $12.58 |
Enterprise Value | $27.56B | $14.20B |
Dividend Yield | — | 8.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Conagra Brands (CAG) trades at $14.985, up 1.39% with neutral technical signals. The company shows mixed fundamentals with a P/E of 10.06 and P/S of 0.63 suggesting undervaluation, but negative net income margin (-16.99%) and ROE (-25.06%) reflect profitability challenges. Recent earnings show two beats and one miss in the last four quarters, with Q3 2026 results pending. The company recently cut its dividend by 50% to prioritize debt reduction and operational improvements under new CEO John Brase.
CAG presents a turnaround story with attractive valuation metrics but faces significant headwinds including declining sales, margin pressure, and high debt levels. Analyst consensus is cautious with 62.5% hold ratings and a $13.67 price target below current levels. The dividend cut provides financial flexibility but signals ongoing challenges. Investors should weigh the discounted valuation against persistent operational pressures and weak growth outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
